KRAS G12C mutation
1 abstract
Abstract
Prevalence of actionable oncogenic alterations (AGA) among patients with advanced (adv) non-squamous (NSQ) non-small cell lung cancer (NSCLC) by age, sex, and race in the United States (US).Org: Merck & Co, Inc., Merck & Co., Inc., Merck and Co, Inc.,